Depixol (Flupentixol) is commonly used in clinical settings where supportive symptom management is appropriate for conditions presenting with acute or episodic manifestations. It is considered relevant for managing symptoms that interfere with daily functioning and may assist with maintaining functional stability over time. The medicine is considered relevant for the maintenance therapy of chronic schizophrenic patients.

Its use is considered relevant for the sustained management of schizophrenia and allied psychotic disorders, as well as in the treatment of features associated with mild to moderate depression. The medication helps address symptom clusters that may become intense or disruptive, specifically by helping to address manifestations such as hallucinations, paranoid delusions, apathy, and low mood. This therapeutic approach is applied in scenarios where short-term symptom management is important, providing relief when symptoms become difficult to tolerate.

“This continuous therapeutic presence may assist with maintaining functional stability and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Psychotic and Affective Symptoms

Property	Description
Primary Domain	Chronic Psychotic Disorders (e.g., Schizophrenia)
Symptom Management	Hallucinations, Delusions, Apathy, Low Mood
Clinical Context	Long-term maintenance therapy; short-term management of depressive features
Patient Benefit	Contributes to easing the overall symptom load; supports functional stability

Regulatory References

1. Health Canada Product Monograph

Who can and cannot use Depixol (Flupentixol)?

Official regulatory documents define strict population eligibility rules for Depixol, based on age, acute health status, and pre-existing conditions.

Absolute Contraindications

Depixol must not be used in patients with known hypersensitivity to flupentixol or other thioxanthenes. Use is also strictly prohibited in individuals experiencing circulatory collapse, a comatose state, or severely depressed consciousness due to intoxication. The injection form is contraindicated in conditions like Phaeochromocytoma and blood dyscrasias.

---

Age and Condition Restrictions

Population Group	Regulatory Status
Children & Adolescents	Not recommended; safety and efficacy are not established.
Older Adults	Use is permitted but requires a reduced initial dosage and close supervision.
Hepatic Impairment	Use with caution; dose reduction and monitoring are advised due to liver metabolism.
Pregnancy	Should not be administered unless the benefit clearly outweighs the theoretical risk.
Lactation	Should not be used as the substance passes into breast milk.

Use requires particular caution in patients with a history of epilepsy, certain cardiovascular disorders (including QT prolongation risk factors), or Parkinson's disease, as stated in official labeling.

Interactions with other medicines and products

The interaction profile of Flupentixol (Depixol) is defined by its central nervous system activity and its potential to affect cardiac conduction, consistent with regulatory classification as a typical antipsychotic. All official interaction information is derived from government regulatory documents.

---

Formal Regulatory Restrictions

Classification	Interacting Entity/Class	Restriction Basis
Contraindicated	Alcohol, Barbiturates, or Opiates	Risk of enhanced sedation and depressed consciousness.
Avoid/Caution	QT-Prolonging Drugs	Documented risk of malignant arrhythmias (e.g., Torsades de Pointes).

---

Documented Interaction Patterns

Flupentixol may enhance the sedative effects of other CNS depressants. Pharmacodynamic interactions include the reduction of effect of levodopa and other adrenergic drugs due to opposing activity, as noted in official prescribing information.

Tricyclic antidepressants and neuroleptics, including Flupentixol, are documented to mutually inhibit the metabolism of each other; this pharmacokinetic interaction can lead to increased plasma concentrations of both classes of medicine. Co-administration with metoclopramide or piperazine is also documented to increase the risk of extrapyramidal disorder. Caution is officially advised in patients with liver damage, as reduced hepatic function may alter drug clearance.

Depixol, containing flupentixol, primarily modulates central nervous system neurotransmission. Its mechanism involves interaction with multiple G-protein coupled receptors, predominantly functioning as an antagonist. The core biological targets are dopamine receptors, specifically demonstrating high binding affinity for both the postsynaptic D1 and D2 receptor subtypes. Flupentixol competitively binds to these receptors, preventing the endogenous ligand, dopamine, from activating them.

This receptor blockade modulates the mesolimbic dopaminergic pathway, resulting in reduced postsynaptic D2 receptor signaling. The reduced D2 activation alters downstream intracellular cascades normally regulated by dopamine binding, ultimately modulating neural excitability. Additionally, flupentixol exhibits antagonistic activity at other targets, including the 5-HT2A serotonin receptors and alpha-1 adrenergic receptors, further contributing to its systemic physiological modulation of central neurotransmitter balance and subsequent neuronal function.

Administration Method

Depixol is typically administered as an intramuscular injection. The medication is delivered into a large muscle, such as the buttock or the upper leg. Because the medication is formulated as an oily solution, it is released slowly into the bloodstream over an extended period.

Frequency of Use

The intervals between administrations are determined based on the specific formulation prescribed and the individual's response to the medication. Injections are generally scheduled at regular intervals, often ranging from every one to four weeks. Maintaining a consistent schedule is a standard aspect of treatment to ensure stable levels of the medication in the body.

Formulations

Depixol is available in different forms, including tablets for oral use and various strengths of injection. The choice of formulation depends on the clinical requirements and the transition between different stages of treatment.

Monitoring Treatment

Regular observation by a healthcare professional is standard practice during the course of treatment. This allows for the assessment of the medication's effects over time. If a scheduled administration is missed, the routine is typically resumed as soon as possible according to the established plan.

Research Evidence / Overview of Studies for Depixol (Flupentixol)

The available research evidence for Flupentixol is drawn from formal clinical trials, large-scale systematic reviews, and meta-analyses. The findings help contribute to the broader evidence landscape by describing how this medicine was evaluated in research settings in specific populations. The evidence highlights what is known — and what is still uncertain.

---

Evidence for Chronic Schizophrenia and Allied Psychotic Disorders

The majority of research related to maintenance support focuses on the long-acting injectable (LAI) form of Flupentixol (Flupentixol Decanoate). Studies explored the relationship between the medicine's continuous presence and observed patient patterns.

These studies prioritized measurements of long-term patient status such as the rates of relapse or the frequency of rehospitalization. Findings describe patterns observed in the studies related to long-term patient status, with reports indicating that the rates of discontinuation from treatment were observed when Flupentixol was compared to other depot preparations. The evidence contributes to the broader evidence landscape when compared to other treatments in research settings.

---

Evidence for Short-term Management of Depressive Features

Research involving Flupentixol explores patient groups characterized by fluctuating or episodic manifestations, such as mild to moderate depression, often presenting with concurrent anxiety. This research was evaluated in randomized controlled trials (RCTs), where the medicine was often compared to either a placebo or other active treatments.

Research highlights changes measured during the study period in depressive and anxiety scores, and patterns related to these measures were noted in some trials compared to placebo in the short term. However, the contribution of Flupentixol as a single agent in research scenarios involving depression is sometimes uncertain because much of the reported short-term evidence is derived from studies of fixed-dose combinations.

---

Research Gaps and Areas of Uncertainty

Evidence quality varies across studies, with many foundational trials being older, and modern, large-scale placebo-controlled trials being limited for the LAI maintenance use. Furthermore, subgroup findings are uncertain for specific comorbid conditions or when trying to apply the results outside of the adult, stabilized population.

Key Studies & References

1. Flupentixol/melitracen (Fixed-dose combination) - Clinical data and indications

Common questions about Depixol (FAQ)

---

Q: Why is Depixol also sometimes prescribed for depression?

Regulatory documents indicate that Depixol (flupentixol) may be used in the management of depression in patients who may or may not be experiencing symptoms of anxiety. Official product information includes this as one of the documented clinical uses of the medicine.

Q: Is Depixol used as a long-term or short-term treatment?

The long-acting injectable (depot) form of this medicine is primarily indicated for the maintenance therapy of chronic conditions. This suggests its use is generally intended to be long-term for maintenance purposes, as documented.

Q: Is it common to feel sleepy or dizzy when starting Depixol treatment?

Yes, official safety information lists somnolence (sleepiness) and dizziness as very common or common side effects. Regulatory documents note that these effects may be most pronounced at the beginning of treatment, and may become less noticeable with continued use.

Q: How long does it usually take to start feeling the effects of Depixol tablets?

According to the official product information, the oral form is designed for initial absorption in the body within hours. Initial signs of benefit are often observed within 2 to 3 days of starting treatment. The substance typically reaches peak blood levels within 3 to 8 hours after taking the tablet.

Q: How long after a Depixol depot injection will the medicine reach its full effect?

The onset of action is typically noted within 24 to 72 hours after injection. Official monographs describe the development of its effects over the course of 2 to 4 weeks.

Q: How long does Depixol stay in the body after the last dose/injection?

The clearance rate varies significantly based on the formulation. The oral form has an elimination half-life of approximately 35 hours. In contrast, the depot injection, which is designed for slow release, has a significantly longer half-life of about 3 weeks.

Q: Do the tablets and the depot injection have the same half-life?

No, the tablets and the depot injection do not have the same half-life. The oral tablets are cleared from the body more quickly, with an elimination half-life of about 35 hours. The depot injection form, designed for extended action, has a half-life of approximately 3 weeks.

Q: Does Depixol cause weight gain, and if so, why?

Weight gain is listed as a common side effect in regulatory documents. Official documentation lists the effect, but the physiological mechanism (the 'why') is not generally detailed in regulatory patient information.

Q: Can Depixol affect a person’s blood sugar or increase the risk of diabetes?

Official warnings state that medicines in this class may be associated with changes in blood sugar levels, specifically hyperglycemia (high blood sugar). These changes mean the medicine can affect the action of medicines used to treat diabetes. Changes in blood sugar levels may warrant monitoring.

Q: Why does Depixol sometimes cause an increase in the hormone prolactin?

Official documentation notes a link between the drug's action and increased prolactin levels (hyperprolactinemia). Its mechanism involves blocking dopamine receptors in the brain. Since dopamine usually acts to inhibit prolactin release, this blockade may lead to higher levels of the hormone circulating in the body.

Q: Does Depixol affect fertility in males or females?

Official information notes a known side effect is hyperprolactinemia (increased prolactin levels). This hormonal change is documented to be linked to potential changes in fertility and amenorrhea (the cessation of menstrual cycles) in women.

Q: Does Depixol increase skin sensitivity to sunlight?

Yes, official safety data lists photosensitivity as an adverse effect of Depixol. Photosensitivity means the medicine can make the skin more reactive or sensitive to light or sunlight.

Q: Can Depixol cause low white blood cell counts, which makes infections more likely?

The official safety profile for the medicine notes that it is associated with blood cell changes. Specifically, leukopenia (a low white blood cell count) has been documented. Official documentation notes that routine blood counts may be considered during treatment.

Q: Does Depixol affect the ability to regulate body temperature (sweating)?

Changes in body temperature (such as high or low temperature) and excessive sweating are listed as potential adverse effects. These effects are noted in official documents, particularly in connection with overdose or Neuroleptic Malignant Syndrome (NMS).

Q: Is it important to mention a family history of blood clots before starting Depixol?

Official warnings describe a need for caution where there is a family history of blood clots. Medicines in this class have been associated with the formation of blood clots ( Venous Thromboembolism or VTE), according to regulatory documents.

Q: Can Depixol be taken with or near organophosphate pesticides?

Regulatory documents describe a need for caution in patients who might be exposed to organophosphorus insecticides (pesticides). This is due to the potential for anticholinergic effects, which can be influenced by the co-occurrence of these substances.

How to Store and Dispose of Depixol

Official regulatory documents mandate specific storage and disposal requirements for Depixol (Flupentixol) to ensure product stability and safety. Requirements often differ between the injection and tablet forms.

---

Storage Conditions

Formulation	Key Requirement
Solution for Injection	Must be stored in the outer carton to protect the contents from light. Some formulations must not be refrigerated or frozen and are stored at room temperature (15 C to 25 C).
Film-Coated Tablets	No special temperature storage conditions are required.

All forms of this medicine must be kept out of the sight and reach of children, as explicitly stated in governmental labeling.

---

Disposal Instructions

Any unused medicinal product or waste material resulting from the use of Depixol must be disposed of in accordance with local requirements. The medicine must not be disposed of via household waste or wastewater unless specifically advised by local authorities.